Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
14 Novembre 2024 - 11:45PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Spruce Biosciences, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of
Securities)
85209E109
(CUSIP Number)
September 30, 2024
(Date of Event Which
Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which
this Schedule is filed:
¨ |
Rule 13d-1(b) |
|
|
x |
Rule 13d-1(c) |
|
|
¨ |
Rule 13d-1(d) |
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall
not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise
subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP
No. 85209E109 |
1. |
Names of Reporting Persons
5AM Opportunities II, L.P. |
2. |
Check
the Appropriate Box if a Member of a Group (See Instructions) |
|
(a)
(b) |
¨
x (1) |
3. |
SEC
Use Only |
4. |
Citizenship or Place of Organization
Delaware |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
5. |
Sole Voting Power
0 |
6. |
Shared Voting Power
1,773,000 shares (2) |
7. |
Sole Dispositive Power
0 |
8. |
Shared Dispositive Power
1,773,000 shares (2) |
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person
1,773,000 shares (2) |
10. |
Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ |
11. |
Percent of Class Represented by Amount in Row (9)
4.1% (3) |
12. |
Type of Reporting Person (See Instructions)
PN |
|
|
|
|
|
(1) | This Schedule 13G is filed by 5AM Opportunities II, L.P. (“Opps II”), 5AM Opportunities II
(GP), LLC (“Opps II GP”), Dr. Kush Parmar (“Parmar”) and Andrew J. Schwab (“Schwab” and, with
Opps II, Opps II GP and Parmar, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as
a “group” for purposes of this Schedule 13G. |
(2) | Includes 1,773,000 shares of Common Stock issuable upon exercise of warrants held by Opps II that are
currently exercisable. Opps II GP is the sole general partner of Opps II and Parmar and Schwab are the managing members of Opps II GP.
Each of Opps II GP, Parmar and Schwab share voting and dispositive power over the shares held by Opps II. |
(3) | This percentage is calculated based upon the sum of (i) 41,302,599 shares of the Common Stock issued
and outstanding as of November 8, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities
and Exchange Commission on November 12, 2024, and (ii) 1,773,000 shares of Common Stock issuable upon exercise of warrants held
by Opps II. |
CUSIP
No. 85209E109 |
1. |
Names of Reporting Persons
5AM Opportunities II (GP), LLC |
2. |
Check
the Appropriate Box if a Member of a Group (See Instructions) |
|
(a)
(b) |
¨
x (1) |
3. |
SEC
Use Only |
4. |
Citizenship or Place of Organization
Delaware |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
5. |
Sole Voting Power
0 |
6. |
Shared Voting Power
1,773,000 shares (2) |
7. |
Sole Dispositive Power
0 |
8. |
Shared Dispositive Power
1,773,000 shares (2) |
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person
1,773,000 shares (2) |
10. |
Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ |
11. |
Percent of Class Represented by Amount in Row (9)
4.1% (3) |
12. |
Type of Reporting Person (See Instructions)
OO |
|
|
|
|
|
(1) | This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as
a “group” for purposes of this Schedule 13G. |
(2) | Includes 1,773,000 shares of Common Stock issuable upon exercise of warrants held by Opps II that are
currently exercisable. Opps II GP is the sole general partner of Opps II and Parmar and Schwab are the managing members of Opps II GP.
Each of Opps II GP, Parmar and Schwab share voting and dispositive power over the shares held by Opps II. |
(3) | This percentage is calculated based upon the sum of (i) 41,302,599 shares of the Common Stock issued
and outstanding as of November 8, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities
and Exchange Commission on November 12, 2024, and (ii) 1,773,000 shares of Common Stock issuable upon exercise of warrants held
by Opps II. |
CUSIP
No. 85209E109 |
1. |
Names of Reporting Persons
Dr. Kush Parmar |
2. |
Check
the Appropriate Box if a Member of a Group (See Instructions) |
|
(a)
(b) |
¨
x (1) |
3. |
SEC
Use Only |
4. |
Citizenship or Place of Organization
United States |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
5. |
Sole Voting Power
0 |
6. |
Shared Voting Power
1,773,000 shares (2) |
7. |
Sole Dispositive Power
0 |
8. |
Shared Dispositive Power
1,773,000 shares (2) |
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person
1,773,000 shares (2) |
10. |
Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ |
11. |
Percent of Class Represented by Amount in Row (9)
4.1% (3) |
12. |
Type of Reporting Person (See Instructions)
IN |
|
|
|
|
|
(1) | This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as
a “group” for purposes of this Schedule 13G. |
(2) | Includes 1,773,000 shares of Common Stock issuable upon exercise of warrants held by Opps II that are
currently exercisable. Opps II GP is the sole general partner of Opps II and Parmar and Schwab are the managing members of Opps II GP.
Each of Opps II GP, Parmar and Schwab share voting and dispositive power over the shares held by Opps II. |
(3) | This percentage is calculated based upon the sum of (i) 41,302,599 shares of the Common Stock issued
and outstanding as of November 8, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities
and Exchange Commission on November 12, 2024, and (ii) 1,773,000 shares of Common Stock issuable upon exercise of warrants held
by Opps II. |
CUSIP
No. 85209E109 |
1. |
Names of Reporting Persons
Andrew J. Schwab |
2. |
Check
the Appropriate Box if a Member of a Group (See Instructions) |
|
(a)
(b) |
¨
x (1) |
3. |
SEC
Use Only |
4. |
Citizenship or Place of Organization
United States |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
5. |
Sole Voting Power
0 |
6. |
Shared Voting Power
1,773,000 shares (2) |
7. |
Sole Dispositive Power
0 |
8. |
Shared Dispositive Power
1,773,000 shares (2) |
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person
1,773,000 shares (2) |
10. |
Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ |
11. |
Percent of Class Represented by Amount in Row (9)
4.1% (3) |
12. |
Type of Reporting Person (See Instructions)
IN |
|
|
|
|
|
(1) | This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as
a “group” for purposes of this Schedule 13G. |
(2) | Includes 1,773,000 shares of Common Stock issuable upon exercise of warrants held by Opps II that are
currently exercisable. Opps II GP is the sole general partner of Opps II and Parmar and Schwab are the managing members of Opps II GP.
Each of Opps II GP, Parmar and Schwab share voting and dispositive power over the shares held by Opps II. |
(3) | This percentage is calculated based upon the sum of (i) 41,302,599 shares of the Common Stock issued
and outstanding as of November 8, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities
and Exchange Commission on November 12, 2024, and (ii) 1,773,000 shares of Common Stock issuable upon exercise of warrants held
by Opps II. |
Item 1. |
|
|
(a) |
Name of Issuer
Spruce Biosciences, Inc. |
|
(b) |
Address of Issuer’s Principal Executive Offices
611 Gateway Boulevard, Suite 740
South San Francisco, CA 94080 |
|
Item 2. |
|
|
(a) |
Name of Person Filing
5AM Opportunities II, L.P. (“Opps II”)
5AM Opportunities II (GP), LLC (“Opps II GP”)
Dr. Kush Parmar (“Parmar”)
Andrew J. Schwab (“Schwab”) |
|
(b) |
Address of Principal Business Office or, if none, Residence
c/o 5AM Ventures
4 Embarcadero Center, Suite 3110
San Francisco, CA 94111 |
|
(c) |
Citizenship |
|
|
|
|
|
|
|
|
|
Entities: |
Opps II |
- |
Delaware |
|
|
|
Opps II GP |
- |
Delaware |
|
|
Individuals: |
Parmar |
- |
United States |
|
|
|
Schwab |
- |
United States |
|
(d) |
Title of Class of Securities
Common Stock, par value $0.0001 per share par value (“Common
Stock”) |
|
(e) |
CUSIP Number
85209E109 |
Item 3. |
If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
|
|
|
Not applicable |
The following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 is provided as of November 14, 2024:
Reporting
Persons | |
Shares Held
Directly | | |
Sole
Voting
Power | | |
Shared
Voting
Power | | |
Sole
Dispositive
Power | | |
Shared
Dispositive
Power | | |
Beneficial
Ownership | | |
Percentage
of Class (2) | |
Opps II (1) | |
| 1,773,000 | | |
| 0 | | |
| 1,773,000 | | |
| 0 | | |
| 1,773,000 | | |
| 1,773,000 | | |
| 4.1 | % |
Opps II GP (1) | |
| 0 | | |
| 0 | | |
| 1,773,000 | | |
| 0 | | |
| 1,773,000 | | |
| 1,773,000 | | |
| 4.1 | % |
Parmar (1) | |
| 0 | | |
| 0 | | |
| 1,773,000 | | |
| 0 | | |
| 1,773,000 | | |
| 1,773,000 | | |
| 4.1 | % |
Schwab (1) | |
| 0 | | |
| 0 | | |
| 1,773,000 | | |
| 0 | | |
| 1,773,000 | | |
| 1,773,000 | | |
| 4.1 | % |
| (1) | Includes
1,773,000 shares of Common Stock issuable upon exercise of warrants held by Opps II that are currently exercisable. Opps II GP is the
sole general partner of Opps II and Parmar and Schwab are the managing members of Opps II GP. Each of Opps II GP, Parmar and Schwab share
voting and dispositive power over the shares held by Opps II. |
| (2) | This
percentage is calculated based upon the sum of (i) 41,302,599 shares of the Common Stock issued and outstanding as of November 8,
2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12,
2024, and (ii) 1,773,000 shares of Common Stock issuable upon exercise of warrants held by Opps II. |
Item 5. |
Ownership of Five Percent or Less of a Class |
|
|
|
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x |
|
Item 6. |
Ownership of More than Five Percent on Behalf of Another Person |
|
|
|
Not applicable |
|
Item 7. |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person |
|
|
|
Not applicable |
|
Item 8. |
Identification and Classification of Members of the Group |
|
|
|
Not applicable |
|
Item 9. |
Notice of Dissolution of Group |
|
|
|
Not applicable |
|
Item 10. |
Certification |
|
|
|
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect. |
Signature
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and correct.
Dated: November 14, 2024
5AM Opportunities II, L.P. |
|
|
|
|
By: |
5AM Opportunities II (GP), LLC |
|
its |
General Partner |
|
|
|
|
By: |
/s/ Kush Parmar |
|
|
|
Name: Dr. Kush Parmar |
|
|
|
Title: Managing Member |
|
|
|
|
5AM Opportunities II (GP), LLC |
|
|
|
|
By: |
/s/ Kush Parmar |
|
|
|
Name: Dr. Kush Parmar |
|
|
|
Title: Managing Member |
|
/s/ Kush Parmar |
|
Dr. Kush Parmar |
|
|
|
/s/ Andrew J. Schwab |
|
Andrew J. Schwab |
|
|
ATTENTION |
|
Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001). |
Exhibit(s):
EXHIBIT A
JOINT FILING AGREEMENT
We, the undersigned, hereby express our agreement that the attached
Schedule 13G (or any amendments thereto) relating to the Common Stock of Spruce Biosciences, Inc. is filed on behalf of each of us.
Dated: November 14, 2024
5AM Opportunities II, L.P. |
|
|
|
|
By: |
5AM Opportunities II (GP), LLC |
|
its |
General Partner |
|
|
|
|
By: |
/s/ Kush Parmar |
|
|
|
Name: Dr. Kush Parmar |
|
|
|
Title: Managing Member |
|
|
|
|
5AM Opportunities II (GP), LLC |
|
|
|
|
By: |
/s/ Kush Parmar |
|
|
|
Name: Dr. Kush Parmar |
|
|
|
Title: Managing Member |
|
/s/ Kush Parmar |
|
Dr. Kush Parmar |
|
|
|
/s/ Andrew J. Schwab |
|
Andrew J. Schwab |
|
Spruce Biosciences (NASDAQ:SPRB)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Spruce Biosciences (NASDAQ:SPRB)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024